Mangoceuticals (MGRX) Other Operating Expenses (2023 - 2026)

Mangoceuticals (MGRX) has 4 years of Other Operating Expenses data on file, last reported at $2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses fell 32.13% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $13.3 million (up 97.7% YoY), and the FY2025 full-year result was -$125624.0, down 102.35% from the prior year.
• Other Operating Expenses rose to $2.1 million in Q1 2026, from -$241976.0 in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $7.3 million in Q3 2025 to a low of -$241976.0 in Q4 2025.
• A 4-year average of $2.3 million and a median of $1.8 million in 2023 frame the typical range for Other Operating Expenses.
• Peak annual rise in Other Operating Expenses reached 453.0% in 2025, while the deepest fall reached 126.78% in 2025.
• Tracing MGRX's Other Operating Expenses over 4 years: stood at $1.9 million in 2023, then tumbled by 52.13% to $903710.0 in 2024, then sank by 126.78% to -$241976.0 in 2025, then soared by 968.35% to $2.1 million in 2026.
• Business Quant data shows MGRX's Other Operating Expenses at $2.1 million in Q1 2026, -$241976.0 in Q4 2025, and $7.3 million in Q3 2025.